FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
20 letters match. Newest first.
-
DrugsJose M. Carpio, M.D.
FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.
Medium -
DrugsMukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre
FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.
High risk -
DrugsEhsan Sadri, M.D.
FDA warns Dr. Ehsan Sadri that two ineligible subjects received an investigational drug in clinical trials.
High risk -
DrugsCenter For Immunology Science, LLC
FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.
High risk -
DrugsPurushothaman Damodara Kumaran, M.D. / Senthil Specialty Hospital
FDA warned Senthil Specialty Hospital and Dr. Purushothaman Damodara Kumaran about missed safety monitoring in a bioequivalence study of an investigational drug.
High risk -
DrugsVerdure Sciences, Inc.
FDA says Verdure Sciences ran a clinical trial of Maplifa without submitting a required IND.
High risk -
DrugsPamela K. Den Besten, DDS, MS
FDA warned sponsor-investigator Pamela K. Den Besten for running a pediatric dental gel study without an IND, enrolling 43 subjects.
High risk -
DrugsShirish M. Gadgeel, M.D.
Detroit clinical investigator Dr. Shirish Gadgeel enrolled ineligible subjects and missed required consent for genetic testing in drug trials.
High risk -
DrugsAmerican Behavioral Research Institute, LLC
FDA warned American Behavioral Research Institute for running a 40-subject Relaxium sleep study without an IND, treating a supplement as a drug.
High risk -
DevicesUnited Health Products, Inc.
FDA warns United Health Products over unapproved significant-risk study of CelluSTAT absorbable hemostat and trial oversight failures.
High risk -
DrugsAmerico F. Padilla, M.D.
FDA warns clinical investigator Americo F. Padilla, M.D. over failing to obtain parental consent before enrolling pediatric subjects in drug trials.
High risk -
DrugsISOThrive, Inc.
ISOThrive ran two human studies of a supplement used as a drug without submitting a required IND.
High risk -
BiologicsMassachusetts Institute of Technology MIT
FDA says MIT's review board for human research failed to make sure consent forms and meeting records met federal rules.
Medium -
DrugsWard Smelling Salts
FDA warns Canadian maker Ward Smelling Salts that its ammonia inhalant products are unapproved new drugs sold illegally in the U.S.
High risk -
DrugsAntonio E. Blanco, M.D./Vista Health Research, LLC
FDA cited Dr. Antonio E. Blanco/Vista Health Research for enrolling ineligible trial subjects and missing required safety imaging.
High risk -
DrugsRandy J. Epstein, M.D./Chicago Cornea Consultants, Ltd.
FDA warns Dr. Epstein/Chicago Cornea Consultants over trial without IND and inadequate drug records.
High risk -
DrugsDaniel Fred Goodman, M.D./Goodman Eye Center
FDA warns Dr. Daniel Fred Goodman/Goodman Eye Center over clinical drug study without required FDA application and missing consent/assent.
High risk -
AnimalEquine Podiatry Solutions, LLC
Equine Podiatry Solutions marketed Desmosphyrine, an unapproved new animal drug, for treating laminitis in horses.
High risk -
DrugsRAAS Nutritionals, LLC/Rare Antibody Antigen Supply, Inc.
FDA says RAAS Nutritionals ran human drug studies without required IND applications, despite claiming products were dietary supplements.
High risk -
DrugsKaleido Biosciences, Inc.
Kaleido Biosciences ran COVID-19 clinical trials of KB109 without required IND, FDA says.
High risk